Introduction: Little is known about the prevalence, prognosis, and response to treatment of advanced NSCLC harboring multiple genomic alterations.
targeted or conventional treatments (progression-free survival [PFS] and objective response rate) were assessed and compared with those of patients harboring single or no mutation.
Results:
We identified 162 patients (0.9%) with double alterations and three with triple mutations. Multiple molecular alterations preferentially involved KRAS (67.3%), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA) (53.3%), and EGFR (42.4%). Patients with multiple alterations were more likely to be male (56.4%), be never-smokers (25.8 versus 34.7%, p < 0.001), and exhibit adenocarcinomas (83.6%). OS did not differ between single and multiple alterations. Patients with EGFR/ KRAS and EGFR/PIK3CA mutations experienced worse PFS than did patients with only EGFR mutations (7.1 and 7.1 versus 14.9 months, p ¼ 0.02 and 0.002, respectively). Conclusions: With almost 1% of patients harboring multiple alterations, the dogma of mutually exclusive mutations should be reconsidered. Although double mutations do not decrease OS, they do alter PFS under first-line treatment for patients with EGFR mutations. Among limited numbers of patients, therapies targeting the dominant oncogene seem to usually remain active.
Introduction
In the last decade, scientists have characterized key molecular alterations that drive lung carcinogenesis, with many demonstrated to play a key role in lung cancer oncogenesis. Patients treated with therapies targeting these oncogenic drivers exhibit better prognoses than those without personalized therapies.
Activating mutations in EGFR have led to the identification of a distinct population of patients with NSCLC. Cancers that harbor EGFR mutations have been demonstrated to possess profound sensitivity to EGFR tyrosine kinase inhibitors (TKIs), giving them a unique biology and natural history. 1 Echinoderm microtubule associated protein like 4 gene (EML4)-anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangement is present in approximately 5% of adenocarcinomas and confers sensitivity to crizotinib and second-and third-generation drugs. 2 Less frequently, mutations or rearrangements occur in other oncogenes, such as erb-b2 receptor tyrosine kinase 2 gene (HER2), BRAF, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA), ROS1, MNNG HOS Transforming gene (MET), or ret proto-oncogene gene (RET). Therapeutics for these mutations are currently being evaluated in clinical trials.
The evolution of tumors bearing a molecular alteration is usually dependent on a single mechanism following the principle of oncogenic addiction, which has been described as the dependence of tumor cells on the specific activity of an activated oncogene. 3 A single mutation or translocation is supposed to confer a survival advantage to the respective cells. Thus, it is commonly accepted that these molecular alterations are mutually exclusive. 4 Nevertheless, case reports and limited series suggest that concomitant molecular alterations can occur in lung cancer and are, perhaps, underestimated. Their impact on response to antitumor agents has scarcely been reported.
In the era of personalized medicine and rapid development of next-generation sequencing, which provide access to the whole genome while increasing detection sensitivity, the probability of facing multiple molecular alterations is likely to increase in the near future. 5 This study, which is based on a nationwide screening program conducted over 1 year, 1 aimed to analyze the largest molecular database so far for concomitant mutations to better characterize the epidemiological characteristics of these patients and their responses to conventional and targeted therapies.
Materials and Methods

Patients
All consecutive patients with NSCLC who were routinely screened for molecular alterations over a 1-year period at one of the 28 certified molecular genetic centers in France were eligible for inclusion in this study. The data were recorded and monitored by the French Cooperative Thoracic Intergroup (IFCT), with the investigators having full access to the deidentified data and analyses for the current report. The database of this program collected the results of 18,679 molecular analyses conducted from April 2012 to April 2013. The prevalence of co-mutations, associated epidemiological characteristics, and impact on prognoses and treatment outcomes were compared with those of patients harboring a single genomic aberration (50.0%). Details are available in the seminal article. catalytic subunit alpha gene (PIK3CA) mutations and ALK rearrangements were done on a routine basis at the molecular genetics centers. Briefly, each molecular genetics center used either the Sanger sequencing method or a more sensitive validated allele-specific technique (generally to be confirmed by Sanger sequencing) to assess EGFR (exons [18] [19] [20] [21] , HER2 (exon 20), BRAF (exon 15), KRAS (exon 2), and PIK3CA (exons 9 and 20) mutations. A certified break-apart fluorescence in situ hybridization assay was used to assess ALK rearrangements. The sequencing techniques used are detailed in Supplementary Table 1 of the germinal article.
1 Additionally, each regional genetics center either did a concurrent analysis of all recommended molecular alterations in the six genes or used a sequential approach in which the EGFR and ALK assessments were done first and each of the other molecular alterations were then assessed until a mutation was found. Multiple alterations reported in this manuscript were found on the same tissue block.
Data Collection
The molecular genetic centers provided the IFCT with the results of molecular assessments of the six genes under investigation and histological typing measured by the referring pathologist. The following data were obtained: sex, ethnic origin, smoking history, family or personal cancer history, performance status, TNM stage, pathological diagnosis, and method of sample collection. Information on treatment types after biomarker analysis and outcomes (best response; firstline treatment and, when applicable, second-line treatment and date[s] of disease progression; and survival status) was reported.
Patients were treated on a routine basis. At the time the study was conducted, erlotinib and gefitinib were approved for first-line treatment of patients with EGFR mutations, whereas crizotinib was available only for second-line treatment of patients with ALK rearrangements. KRAS, BRAF, HER2, and PIK3CA mutations were targetable by drugs available either through clinical trials or off label. Other emerging targets such as ROS1, MET, and RET were not analyzed at the time of data collection.
Ethical Considerations
The study was approved by a national ethics committee for observational studies (National ethics committee for observational studies), by the French Advisory Committee on Information Processing in Material Research in the Health field, and by the National Commission of Informatics and Liberty according to French laws. All patients with NSCLC included in this study received information from their institution or referring clinician in line with French laws. Patients were not required to provide written informed consent to be included in the study.
Statistics
The primary study objective was to determine the frequency of multiple molecular alterations among six genes that were routinely screened through a nationwide approach in consecutive patients with NSCLC. The secondary objectives were to describe the epidemiological particulars of this patient population and to compare their prognoses and responses to targeted or conventional therapies (overall survival [OS], progression-free survival [PFS] , and response rate [RR]) with those observed in patients with single mutations.
Descriptive statistics, including median and range or quartiles for continuous variables and frequencies and percentages for categorical variables, were used. Median follow-up duration was defined as the time from the molecular analysis assessment date to the closing date of the analysis (December 31, 2015). First-line PFS was defined as the time from the molecular analysis assessment date to the date of first progression or death from any cause. Second-line PFS was defined as the time from initiation of second-line treatment to the date of second progression or death from any cause. OS was defined as the time from the molecular analysis assessment date to the date of death or final follow-up. Survival curves were estimated by the Kaplan-Meier method for the total population of patients with mutations and for groups of interest. We compared the groups of interest by using a two-sided log-rank test. Patient characteristics (with single or without double alterations and of each biomarker or biomarker association) were compared by using the chi-square test for qualitative variables or a nonparametric test for quantitative variables. Univariate Cox models were applied to select the most promising prognostic variables (threshold p ¼ 0.20). A multivariate Cox model was then used to adjust for potential confounders (clinical or molecular characteristics associated with PFS or OS). Adjusted hazard ratios with 95% confidence intervals were calculated. All statistical tests were two sided, and a p value less than 0.05 was deemed statistically significant. All analyses were performed with SAS software, version 9.3 (SAS Institute Inc., Cary, NC).
Results
Prevalence of Multiple Genetic Alterations in Nonsquamous NSCLC
Out of 17,826 patients, we identified 165 (0.93%) with multiple genetic alterations involving oncogenic drivers, including 162 double mutations (0.91%) and three triple mutations (0.02%). Double or triple mutations involving EGFR (including sensitizing and resistant mutations) represented 42.4% of all multiple alterations (n ¼ 70). The most common co-mutations occurring de novo with EGFR were PIK3CA (n ¼ 28), KRAS (n ¼ 24), ALK (n ¼ 10), and BRAF (n ¼ 5) mutations. Concomitant mutations associated with KRAS represented 67.3% of all multiple alterations (n ¼ 111), with the most frequent partners being PIK3CA (n ¼ 53), EGFR (n ¼ 24), ALK (n ¼ 22), and BRAF (n ¼ 9) mutations. The prevalence of each association has been detailed in Table 1 .
Characteristics of Patients Harboring Multiple Mutations
Multiple molecular alterations were observed more frequently in males (56.4% [p < 0.001]) with a median age of 67 years, in never-smokers or former smokers (34.7% versus 39.8%), and almost exclusively in patients with adenocarcinoma (83.6%). The epidemiology of patients harboring multiple molecular alterations is very similar to that of those harboring a single mutation, yet with a slightly higher percentage of never-smokers. These epidemiological data have been detailed in Table 2 . 
Overall Outcome in Patients Harboring Multiple Mutations
Predictive Impact of Multiple Mutations on Response to Targeted Therapy in Patients Harboring Concomitant Mutations
Response to first-line therapy with a EGFR TKI tended to be negatively influenced by a concomitant PIK3CA mutation (ORR ¼ 60.9% for patients with EGFR mutation versus 45.5% for patients with a PIK3CA co-mutation [p ¼ 0.30]). Among 24 patients with EGFR/KRAS co-mutation, data concerning first-line therapy were available for only seven patients. Only two received EGFR TKI as first-line therapy, resulting in one partial response and one case of disease progression. Three patients with EGFR/KRAS co-mutation received EGFR TKIs as second-line therapy, resulting in one partial response and two cases of progressive disease, whereas 172 patients with EGFR mutation who received this treatment in a second-line setting showed a 47.7% ORR and 23.8% rate of disease progression (Fig 3) .
Patients treated with crizotinib in a first-line setting for NSCLC harboring ALK rearrangement concomitantly with other molecular alterations tended to experience a lower RR, although the number of patients was too small to achieve significant results (Fig. 3D) . The only patient harboring ALK and EGFR mutations, along with two patients with KRAS/ALK mutations, exhibited stable disease as the best response to crizotinib, whereas patients with ALK rearrangement showed a 69.5% ORR to crizotinib. One patient with BRAF/ALK-rearranged adenocarcinoma showed a partial response.
No sufficient data were available concerning therapy targeting KRAS, BRAF, HER2. or PIK3CA in co-mutated patients.
Predictive Impact of Multiple Mutations on Response to Chemotherapy
No significant difference in RR to chemotherapy was observed between the populations of patients harboring single or multiple molecular aberrations. Response to first-line chemotherapy was not influenced by a concomitant mutation or rearrangement occurring with KRAS (ORR ¼ 41.7% versus 37.2% and disease control rate ¼ 58.3% versus 59.9% [p ¼ 0.85] for multiple versus single mutation, respectively). No difference in terms of response to first-line chemotherapy has been identified for ALK-rearranged tumors, regardless of the partner (EGFR, KRAS, or BRAF). In a second-line setting, chemotherapy seemed more efficient when a second mutation was associated with KRAS, although the difference was not statistically significant (33.3% versus 15.5% ORR, respectively) (Fig 4) .
The impact of the most frequent combination of genomic alterations on the prognosis and response to conventional and targeted therapy has been summarized in Table 3 .
Discussion
Here we have presented the largest cohort of patients harboring multiple genomic alterations driving NSCLC (n ¼ 165), with a prevalence of 0.93%. Little is known about this rare population of patients who constitute a real challenge for clinicians, especially from a therapeutic point of view. Deep sequencing will likely increase the incidence of multiple genetic alterations with undefined theranostic impact. Therefore, it seems crucial to decipher the effect of different combinations of basic oncogenes before facing complex molecular signatures. A previous study reported 153 double mutations and seven triple mutations in a cohort of 5125 patients from China. 6 In this study, the prevalence of double or more mutations was higher (3%) than in ours, yet the epidemiological characteristics of the two study populations were clearly different. Whereas the overall rate of mutations was similar (48.4% versus 49.5% in the IFCT Biomarkers France study 1 ), the mutation profile was very different between the two study populations, with a predominance of EGFR mutations (36.2% versus 11%) and low rate of KRAS mutations (8.4% versus 29%) compared with in our white population. In another Chinese study involving stage IB resected lung adenocarcinomas, double mutations were found in 8.3% of cases (13 of 156). EGFR mutations were present in 44.2% of tumors and involved in 10 of 13 co-mutated tumors. 7 Nevertheless, unlike our study, neither of these studies included ALK rearrangement and allowed analysis of either patient prognosis or response to targeted and conventional therapies. The Lung Cancer Mutation Consortium reported data on 1007 lung adenocarcinomas. Overall, 27 of 1007 patients (2.7%) Figure 1 . Overall survival (OS) in the presence of double mutation involving EGFR compared to EGFR mutated patients. (A) OS in patients harboring double mutation involving EGFR (EGFRþX) compared to EGFR mutated patients. (B) OS in the presence of EGFR and PI3K co-mutation compared to EGFR mutated patients. (C) OS in the presence of EGFR and ALK comutation compared to EGFR mutated patients. (D) OS in the presence of EGFR and KRAS co-mutation compared to EGFR mutated patients. IC95%, concentration that inhibits 95%; HR, hazard ratio; NR, not reached.
harbored two oncogenic driver mutations. However, in this study, the spectrum of genes tested was larger (EGFR, KRAS, erb-b2 receptor tyrosine kinase 2 gene [ERBB2], AKT/serine threonine kinase 1 gene [AKT1], BRAF, mitogen-activated protein kinase kinase gene [MEK1], NRAS, and PIK3CA). The molecular epidemiology of this population was also slightly different, with (in particular) a higher prevalence of EGFR mutations (22%) and ALK rearrangements (8.5%). Furthermore, the double mutations observed in this study were different, including 14 with two small mutations and 13 with either a small mutation and ALK rearrangement (four); a small mutation and MET amplification (seven); concurrent ALK rearrangement and MET amplification (two) and one case had EGFR ex19del and AKT1. Of the 14 cases with two small mutations, 13 (92%) had a PIK3CA mutation in addition to another mutation, including nine with EGFR, two with BRAF, one with KRAS, and one with MEK1 mutation. In this study, however, neither prognosis nor outcome of these patients was reported. 8, 9 In patients with EGFR mutation, we observed a detrimental effect of a concomitant KRAS or PIK3CA mutation on prognosis. PFS was logically lower when one of these two oncogenes, which are implicated in downstream signaling pathways, was mutated. With a prevalence of 10% to 15% for EGFR and 30% for KRAS reported in white patients, the probability of observing a concomitant mutation of these two oncogenes can be assumed to be about 3%. 10 However, this association appears much more rarely (n ¼ three of 731 11 and n ¼ 29 of 5125 6 ), with descriptions in the literature limited to isolated clinical cases or short series, 6, [11] [12] [13] [14] [15] so that these mutations have usually been considered to be mutually exclusive. 4 In our study, we have reported 27 cases of EGFR/KRAS-co-mutant tumors. PFS was twice as low for patients with EGFR/KRAS mutation as for patients with EGFR mutation. KRAS mutations were shown to cause the loss of the guanosine triphosphatase activity, along with its subsequent feedback regulation. KRAS then continuously activates BRAF and PIK3CA, independently of EGFR. This can explain why KRAS mutations are usually associated with a poor RR to an EGFR TKI. [16] [17] [18] However, responses in the short term have been reported in small series. 12, 15 In our study, first-line treatment was available for only seven patients, with only one treated with an EGFR TKI, resulting in a partial response. KRAS and EGFR mutations were likely carried by two different clones, with initial response but shorter PFS accounted for by the emergence of a KRASresistant clone, as observed in the series of Benesova et al., in which patients had partial responses but short PFS (3, 5, and 7 months 12 ). Taken together, all these data explain, as reported in Li's large Chinese cohort in which only 13.1% of patients received EGFR TKIs in the firstline setting, why clinicians are reluctant to prescribe EGFR TKIs in the presence of KRAS mutation, regardless of EGFR status. Nevertheless, our study, which is in line with other small series, seems to suggest that EGFR TKIs could be considered for these patients as first-line therapy. On the other hand, when these agents were given in a second-line setting, poor results (one partial and two progressive responses) were found, probably because previous chemotherapy proved effective on EGFR but not on a KRAS clone, this latter mutation being associated with chemoresistance. 18 Obviously, the very limited number of patients harboring double mutations involving EGFR does not allow drawing definitive conclusions.
Up to now, PIK3CA has been shown to be mutated in 5% to 10% of squamous cell carcinomas and 2% to 3% of adenocarcinomas, which is associated with disappointing results when PIK3CA or mammalian target of rapamycin inhibitors are used.
19 PIK3CA mutations also seem to be associated with poor RR to EGFR TKIs. 20 Moreover, introducing PIK3CA mutation into EGFR mutant cell lines was reported to abrogate sensitivity to EGFR TKIs. 21 PFS in our study also tended to be lower for patients with PIK3CA/EGFR mutation than for patients with EGFR mutation (p ¼ 0.02). However, although responses to EGFR TKI tended to be influenced by a concomitant PIK3CA mutation, the 45.5% RR indicates that these agents should nonetheless be considered as first-line treatment of EGFR/PIK3CA co-mutated tumors. Chaft et al. reported objective and durable responses to EGFR TKI for three EGFR/PIK3CA co-mutated tumors. 22 Moreover, although Eng et al. corroborated a detrimental impact of an additional PIK3CA mutation in EGFR-mutant adenocarcinomas on prognosis, sensitivity to EGFR TKIs was not significantly affected and median duration response was the same in both groups. 23 Because of a similar epidemiology, the association of EGFR mutations and ALK rearrangement has been studied extensively. These two alterations are often considered mutually exclusive. 24, 25 Among 1683 NSCLC tumors analyzed by Gainor et al. (including 301 EGFR-mutated and 75 ALK-rearranged tumors), no co-mutation was detected. 25 These data are concordant with the results of a meta-analysis conducted by Wang et al. in which only 0.75% of patients (three of 399) with EGFR mutations also harbored ALK rearrangement. 26 However, numerous clinical cases (n ¼ 43) have been reported and collected in a recent review of case series, leading to the conclusion of a 1.5% prevalence for ALK rearrangement in patients with EGFR mutation. 27 In addition, Rosell et al. reported on a population of 95 EGFR-mutated adenocarcinomas (EURTAC trial), with a 15.8% prevalence of concomitant ALK rearrangement, although this result was probably accounted for by the low specificity of the polymerase chain reaction assay. 28 Because of the co-expression in IHC of ALK fusion protein and abnormal EGFR (specific antibodies of different mutations), these two molecular abnormalities can co-exist in the same cell. 27, 29, 30 In our study, a concomitant mutation of EGFR, KRAS, or PIK3CA had no detrimental impact on PFS or OS. Response to firstline treatment by chemotherapy seemed very similar, regardless of the second mutation. Nevertheless, although the number of patients was too small, a coalteration could likely change sensitivity to crizotinib: two of two patients with ALK/KRAS mutation and one patient with ALK/EGFR mutation showed only stable disease as the best response. Obviously, these findings involve too limited a number of patients not to consider crizotinib as a first-line choice in patients with ALK/ EGFR or ALK/KRAS mutations. In the particular context of patients with EGFR/ALK mutations, it is very difficult to define the best treatment sequence. The allelic fraction of each alteration in the next-generation sequencing report should help in choosing the clone to target first.
To the best of our knowledge, there are no data on combined treatment with ALK and EGFR TKI in this setting. Interestingly, although the poor prognosis associated with KRAS mutations has been well established, 18 these data remained valid in the presence of a concomitant molecular alteration, even if the latter was known to be associated with good prognosis. Moreover, response to chemotherapy was not improved by the concomitant presence of ALK rearrangement or EGFR mutation (Fig. 4) . We can thus conclude that the detrimental impact of KRAS mutations on prognosis and response to platinum-based chemotherapy proved independent of other oncogenes.
In conclusion, we have herein reported on the largest cohort of patients with tumors harboring multiple molecular alterations. The tenet of mutual exclusivity of genomic aberrations toward each other is likely to be questioned. Our results suggest a detrimental effect of concomitant PIK3CA or KRAS mutations on both prognosis and sensitivity to EGFR TKI in patients harboring EGFR mutations. Even if the number of patients is low, responses of these tumors to TKIs seem to remain high enough to consider these agents as a first-or second-line regimen. The determination of the respective allelic fraction of each mutation would be of interest to assess the relative importance of each mutation and help in the choice of the first-line therapy.
